Immunotech Laboratories Inc. Announces Breakthrough Results for HIV and AIDS Treatment for Terminal Salvage Patients
November 28 2012 - 1:31PM
Marketwired
Immunotech Laboratories, Inc. (PINKSHEETS: IMMB)
Pursuant to significantly positive results with its patient
population targeting full blown AIDS patients, the company has
completed numerous clinical contracts with Mexican hospitals to
initiate a full blown effort of clinical trial protocol preparation
for its HIV/AIDS Vaccine drug candidate. The successful outcome of
these efforts will eventually provide the necessary regulatory
means for its product's registration approval in the Republic of
Mexico and eventually open a venue to most of the central and South
American markets.
Resistance to all commercially available antiretroviral (ARV)
agents within all classes has been reported. The occurrence of
multi-class resistance remains high, with 20% of infected
individuals developing resistance to two or more classes within six
years of initiating treatment, and 10% of newly diagnosed
infections already resistant to at least one class in the U.S.
Multi-class resistance is even more prevalent in disenfranchised
patient populations, whose rates of successful adherence to even
the most simplified regimens available remains prohibitively low.
Inactivated Pepsin Fraction (IPF), like other natural autoantibody
based fractionated proteins, has an affinity to pathogenic binding
and simultaneously produces effects of immune homeostasis. IPF has
shown significant antiretroviral activity via immune stimulatory
pathways in vitro, notably helper T1 cells elaborate cytokines
INFy, IL-2. These cells selectively promote cell-mediated immune
responses that are disadvantageous to viral replication.
IPF appears to modulate helper T1 cells' expression of elaborate
cytokines INFy, IL-2, which selectively promote cell-mediated
immune response and subsequently stimulate cytotoxic lymphocytes.
These lymphocytes have a prominent role in the host's immunologic
response to HIV infection. Proteins encoded by these pathogens
enter the endogenous pathway for antigen presentation and are
expressed on the surface of the infected cell as a complex with
class l MHC- proteins. IPF appears to present a novel mechanism to
reduce viral burden and stimulate immune responses to the virus for
patients with significant antiretroviral resistance. Furthermore,
the use of IPF with antiretroviral therapy reduces the viral load
between two and five log reduction.
Further information can be obtained from
www.immunotechlab.com
This news release contains forward-looking statements that
involve risks and uncertainties associated with financial
projections, budgets, milestone timelines, clinical development,
regulatory approvals, and other risks described by Immunotech
Laboratories, Inc. from time to time in its periodic reports filed
with the SEC. IPF is not approved by the US Food and Drug
Administration or by any comparable regulatory agencies elsewhere
in the world. While Immunotech Laboratories believes that the
forward-looking statements and underlying assumptions contained
therein are reasonable, any of the assumptions could be inaccurate,
including, but not limited to, the ability of Immunotech
Laboratories to establish the efficacy of IPF in the treatment of
any disease or health condition, the development of studies and
strategies leading to commercialization of IPF in the United
States, the obtaining of funding required to carry out the
development plan, the completion of studies and tests on time or at
all, and the successful outcome of such studies or tests.
Therefore, there can be no assurance that the forward-looking
statements included in this release will prove to be accurate. In
light of the significant uncertainties inherent in the
forward-looking statements included herein, Immunotech Laboratories
or any other person that the objectives and plans of Immunotech
Laboratories will be achieved should not regard the forward-looking
statements as a representation.
Contact: Harry Zhabilov President and Chief Science Officer
Telephone: 818-409-9091 Fax: 626-703-4172 info@immunotechlab.com
www.immunotechlab.com
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Immunotech Laborator (CE) (USOTC:IMMB)
Historical Stock Chart
From Oct 2023 to Oct 2024